Der tenosynoviale Riesenzelltumor - eine retroperspektive Analyse über 15 Jahre

Eine retrosperspektive Studie über 15 Jahre über den tenosynovialen Riesenzelltumor

Tears, blushes and beating hearts: Masculinity, emotions and feelings in Elizabeth Gaskell's North and South, Thomas Hardy's Far from the Madding Crowd and Sara Jeannette Duncan's The Imperialist.

This dissertation explores the relationship between masculinity, emotions and feelings in Elizabeth Gaskell’s North and South (1855), Thomas Hardy’s Far from the Madding Crowd (1874) and Sara Jeannette Duncan’s The Imperialist (1904). The Introduction gives an overview of gender theory and the ideology of masculinity in general, explains the terms ‘emotion’ and ‘feeling’ and discusses the relationship between the ideology of masculinity, emotions and feelings in the nineteenth century. Chapter One examines the relationship between masculinity, emotions and feelings in the industrial setting of North and South and studies the tension or discrepancy between them. In addition, it demonstrates the different functions of the display of emotions and feelings. Furthermore, it challenges the assumption that the expression of male emotions and feelings automatically emasculates a man. Chapter Two looks at the depiction of masculinity and emotions in relation to nature descriptions, such as landscape, weather and animals, in the rural setting of Far from the Madding Crowd. It further shows how the display of emotions changes in the second half of the nineteenth century to an indirect expression through nature descriptions. At the same time, this chapter indicates that emotions and feelings are natural for men and that their suppression can have destructive consequences. The final chapter investigates masculine identities in the imperial setting of The Imperialist. It shows how at the-turn-of-the 20th century the expression of male emotions and feelings is replaced by an increasing self-control. The Conclusion indicates the realignment of gender identities that are defined through the inclusion of feminine and masculine characteristics and demonstrate their application in further nineteenth-century texts

Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

<p>Abstract</p> <p>Background</p> <p>Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer.</p> <p>Methods</p> <p>Acutely-ill, non-surgical patients ≥70 years with (n = 274) or without cancer (n = 2,965) received certoparin 3,000 UaXa o.d. or UFH 5,000 IU t.i.d. for 8-20 days.</p> <p>Results</p> <p>1) Thromboembolic events in cancer patients (proximal DVT, symptomatic non-fatal PE and VTE-related death) occurred at 4.50% with certoparin and 6.03% with UFH (OR 0.73; 95% CI 0.23-2.39). Major bleeding was comparable and minor bleedings (0.75 vs. 5.67%) were nominally less frequent. 7.5% of certoparin and 12.8% of UFH treated patients experienced serious adverse events. 2) Thromboembolic event rates were comparable in patients with or without cancer (5.29 vs. 4.13%) as were bleeding complications. All cause death was increased in cancer (OR 2.68; 95%CI 1.22-5.86). 10.2% of patients with and 5.81% of those without cancer experienced serious adverse events (OR 1.85; 95% CI 1.21-2.81).</p> <p>Conclusions</p> <p>Certoparin 3,000 UaXa o.d. and 5,000 IU UFH t.i.d. were equally effective and safe with respect to bleeding complications in patients with cancer. There were no statistically significant differences in the risk of thromboembolic events in patients with or without cancer receiving adequate anticoagulation.</p> <p>Trial Registration</p> <p>clinicaltrials.gov, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00451412">NCT00451412</a></p

The hearth of reform: print activism and emotions in Canadian women’s writing, 1890-1914

Abstract not currently available

Biological Activity of Low-Molecular-Weight Heparin Increases Over 9 Days in Patients Treated for Acute Venous Thromboembolism.

Abstract Abstract 4176 Subcutaneous (s.c.) body-weight adjusted as well as fixed dose low-molecular-weight heparin (LMWH) for treatment of acute venous thromboembolism (VTE) has been proven to be at least as effective and safe as intravenous unfractionated heparin (UFH). We hypothesized that the anticoagulant effects of LMWH may accumulate during a 9 days fixed dose therapy in patients with acute VTE. Ten patients received 8,000 IU LMWH certoparin bid s.c. for 9±1 days after having given written informed consent. The local ethics committee accepted the study protocol. Serial blood and urine were collected at days 2 and 9 and daily before and after the morning administration of the anticoagulant. The pharmacodynamic parameters were analysed on the anti-factor Xa S2222 method (aXa), heptest, thrombin generation inhibition assay (TGIA), and tissue factor pathway inhibitor activity (TFPI). The area under the activity time curves (AUC) of the parameters was compared at days 2 and 9. LMWH reached steady state levels of the S2222 and heptest assay within 24 hrs. aXa, heptest, TGIA and TFPI were 22%, 38%, 13% and 22% higher at day 9 compared to day 2. The elimination half-lives of aXa and heptest and the aXa excreted into the urine did not differ between days 2 and 9, respectively. The AUC of the aXa did not correlate with the body weight of the patients. Fixed dose, body weight-independent subcutaneous LMWH accumulated to some extend after 9 days of treatment in patients with acute VTE. However, the results of the clinical trials with the LMWH certoparin did not show more bleeding complications compared to UFH. Therapy with LMWH for more than 10 days may require dose reduction. Disclosures: Harenberg: Bristol-Myers Squibb: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi Aventis: Consultancy, Honoraria; Roche Diagnostics: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bayer Health Care: Consultancy, Honoraria. Abletshauser:Novartis: Employment. </jats:sec